Bicycle Therapeutics PLC (BCYC)
20.70
+0.44
(+2.17%)
USD |
NASDAQ |
Nov 22, 11:05
Bicycle Therapeutics Enterprise Value: 508.01M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 508.01M |
| November 20, 2024 | 514.91M |
| November 19, 2024 | 523.20M |
| November 18, 2024 | 521.82M |
| November 15, 2024 | 613.65M |
| November 14, 2024 | 668.20M |
| November 13, 2024 | 712.39M |
| November 12, 2024 | 726.20M |
| November 11, 2024 | 788.34M |
| November 08, 2024 | 832.53M |
| November 07, 2024 | 814.57M |
| November 06, 2024 | 741.39M |
| November 05, 2024 | 732.41M |
| November 04, 2024 | 728.96M |
| November 01, 2024 | 677.17M |
| October 31, 2024 | 727.92M |
| October 30, 2024 | 768.31M |
| October 29, 2024 | 798.69M |
| October 28, 2024 | 820.79M |
| October 25, 2024 | 815.90M |
| October 24, 2024 | 818.66M |
| October 23, 2024 | 856.62M |
| October 22, 2024 | 918.05M |
| October 21, 2024 | 951.87M |
| October 18, 2024 | 974.64M |
| Date | Value |
|---|---|
| October 17, 2024 | 954.63M |
| October 16, 2024 | 1.008B |
| October 15, 2024 | 978.78M |
| October 14, 2024 | 916.67M |
| October 11, 2024 | 935.30M |
| October 10, 2024 | 837.30M |
| October 09, 2024 | 805.55M |
| October 08, 2024 | 733.08M |
| October 07, 2024 | 724.11M |
| October 04, 2024 | 737.92M |
| October 03, 2024 | 641.29M |
| October 02, 2024 | 666.14M |
| October 01, 2024 | 676.49M |
| September 30, 2024 | 670.97M |
| September 27, 2024 | 670.88M |
| September 26, 2024 | 678.47M |
| September 25, 2024 | 680.54M |
| September 24, 2024 | 697.79M |
| September 23, 2024 | 723.32M |
| September 20, 2024 | 822.67M |
| September 19, 2024 | 828.88M |
| September 18, 2024 | 750.23M |
| September 17, 2024 | 753.68M |
| September 16, 2024 | 792.31M |
| September 13, 2024 | 933.75M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
6.585M
Minimum
Jun 16 2022
1.568B
Maximum
Nov 15 2021
493.28M
Average
461.55M
Median
May 17 2023
Enterprise Value Benchmarks
| Adaptimmune Therapeutics PLC | 26.67M |
| NuCana PLC | -11.87M |
| TC BioPharm (Holdings) PLC | -0.927M |
| Autolus Therapeutics PLC | 98.72M |
| Biodexa Pharmaceuticals PLC | -3.355M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -50.80M |
| Revenue (Quarterly) | 2.676M |
| Total Expenses (Quarterly) | 66.20M |
| EPS Diluted (Quarterly) | -0.74 |
| Profit Margin (Quarterly) | -1.90K% |
| Earnings Yield | -15.89% |
| Normalized Earnings Yield | -15.84 |